Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Overview of screening assays used to evaluate PROTACs for cancer treatment. Local targets link to admitted publications; unresolved targets remain external evidence.
Targeting of the FOXM1 oncoprotein by E3 ligase-assisted degradation
10.1021/acs.jmedchem.1c01069 · 2021 · External reference
PROTAC targeted protein degraders: the past is prologue
10.1038/s41573-021-00371-6 · 2022 · External reference
An overview of PROTACs: a promising drug discovery paradigm
10.1186/s43556-022-00112-0 · 2022 · External reference
Critical assessment of targeted protein degradation as a research tool and pharmacological modality
10.1016/j.tips.2020.02.006 · 2020 · External reference
PROTACs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
10.1073/pnas.141230798 · 2001 · External reference
PROTACs: past, present and future
10.1039/d2cs00193d · 2022 · External reference
A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs
2023 · External reference
Critical parameters in targeted drug development: the pharmacological audit trail
10.1053/j.seminoncol.2016.06.001 · 2016 · External reference
NDA submission of vepdegestrant (ARV-471) to U.S. FDA: the beginning of a new era of PROTAC degraders
10.1021/acs.jmedchem.5c01818 · 2025 · External reference
Unresolved reference
External reference
Molecular glues and PROTACs in targeted protein degradation: mechanisms, advances, and therapeutic potential
10.1016/j.bcp.2025.117297 · 2025 · External reference
Molecular glue degraders: rational design, specificity engineering, and advanced delivery
10.1016/j.apsb.2026.02.020 · 2026 · External reference
Assays and technologies for developing proteolysis targeting chimera degraders
10.4155/fmc-2020-0073 · 2020 · External reference
Binding affinity determination in drug design: insights from lock and key, induced fit, conformational selection, and inhibitor trapping models
10.3390/ijms25137124 · 2024 · External reference
Insights into protein-ligand interactions: mechanisms, models, and methods
10.3390/ijms17020144 · 2016 · External reference
DELs enable the development of BRET probes for target engagement studies in cells
10.1016/j.chembiol.2023.06.019 · 2023 · External reference
Design, synthesis, and biological evaluation of small molecule PROTACs for potential anticancer effects
10.1007/s00044-019-02485-4 · 2019 · External reference
Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
10.7150/thno.75444 · 2022 · External reference
Degradation of polo-like kinase 1 by the novel poly-arginine N-degron pathway PROTAC regulates tumor growth in nonsmall cell lung cancer
10.1021/acs.jmedchem.3c01493 · 2024 · External reference
Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer
10.1016/j.apsb.2020.11.022 · 2021 · External reference
Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression
10.1021/acs.jmedchem.8b00909 · 2019 · External reference
Development of the first geldanamycin-based HSP90 degraders
10.3389/fchem.2023.1219883 · 2023 · External reference
Discovery of a potent, cooperative, and selective SOS1 PROTAC ZZ151 with in vivo antitumor efficacy in KRAS-mutant cancers
10.1021/acs.jmedchem.3c00075 · 2023 · External reference
Lessons in PROTAC design from selective degradation with a promiscuous warhead
10.1016/j.chembiol.2017.09.010 · 2018 · External reference
PROTAC 2.0: expanding the frontiers of targeted protein degradation
10.1016/j.drudis.2025.104376 · 2025 · External reference
Fluorescence polarization assays in small molecule screening
10.1517/17460441.2011.537322 · 2011 · External reference
Fluorescence polarization: past, present and future
10.2174/138620703106298347 · 2003 · External reference
Fluorescence polarization immunoassay: detection of antibody to Brucella abortus
10.1006/meth.2000.1038 · 2000 · External reference
Plasticity in binding confers selectivity in ligand-induced protein degradation
10.1038/s41589-018-0055-y · 2018 · External reference
Analysis of protein-ligand interactions by fluorescence polarization
10.1038/nprot.2011.305 · 2011 · External reference
Surface plasmon resonance: towards an understanding of the mechanisms of biological molecular recognition
10.1016/s1367-5931(00)00251-9 · 2001 · External reference
Discovery of the first potent DYRK2 proteolysis targeting chimera degraders
10.1021/acsmedchemlett.4c00065 · 2024 · External reference
A novel strategy to block mitotic progression for targeted therapy
10.1016/j.ebiom.2019.10.013 · 2019 · External reference
Targeted degradation of SOS1 exhibits potent anticancer activity and overcomes resistance in KRAS-mutant tumors and BCR-ABL-positive leukemia
10.1158/0008-5472.can-24-1093 · 2025 · External reference
Discovery of the first-in-class agonist-based SOS1 PROTACs effective in human cancer cells harboring various KRAS mutations
10.1021/acs.jmedchem.1c01774 · 2022 · External reference
Discovery of precision targeting EZH2 degraders for triple-negative breast cancer
10.1016/j.ejmech.2022.114462 · 2022 · External reference
Plasmonic nanoholes in a multichannel microarray format for parallel kinetic assays and differential sensing
10.1021/ac802276x · 2009 · External reference
Real-time and label-free bio-sensing of molecular interactions by surface plasmon resonance: a laboratory medicine perspective
2012 · External reference
Overcoming limitations of FRET measurements
10.1002/cyto.a.22851 · 2016 · External reference
A substrate-independent TR-FRET histone deacetylase inhibitor assay
10.1177/1087057111422102 · 2011 · External reference
First-in-class small molecule degrader of pregnane X receptor enhances chemotherapy efficacy
10.1021/acs.jmedchem.4c01926 · 2024 · External reference
Survey of the year 2008: applications of isothermal titration calorimetry
10.1002/jmr.1025 · 2010 · External reference
Survey of the year 2005: literature on applications of isothermal titration calorimetry
10.1002/jmr.803 · 2007 · External reference
10.3791/2796
10.3791/2796 · External reference
Biophysical approaches to study actinoporin-lipid interactions
10.1016/bs.mie.2020.12.017 · 2021 · External reference
Small-molecule ferritin degrader as a pyroptosis inducer
10.1021/jacs.3c01852 · 2023 · External reference
N-degron-based PROTAC targeting PLK1: a potential therapeutic strategy for cervical cancer
10.3390/pharmaceutics17081027 · 2025 · External reference
Target engagement assays in early drug discovery
10.1021/acs.jmedchem.4c03115 · 2025 · External reference
High-throughput cellular thermal shift assay using acoustic transfer of protein lysates
10.1021/acschembio.1c00760 · 2022 · External reference
Applications of the cellular thermal shift assay to drug discovery in natural products: a review
10.3390/ijms26093940 · 2025 · External reference
A robust CETSA data analysis automation workflow for routine screening
10.1016/j.slasd.2024.100172 · 2024 · External reference
Rapid evaluation of small molecule cellular target engagement with a luminescent thermal shift assay
10.1021/acsmedchemlett.1c00276 · 2021 · External reference
NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion
10.1016/j.apsb.2021.12.017 · 2022 · External reference
Design and synthesis of EZH2-based PROTACs to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2
10.1021/acs.jmedchem.0c02234 · 2021 · External reference
A novel matrine derivative B10 exerts its anti-liver cancer activity in vitro and in vivo via targeting FGFR3/PI3K/AKT signaling pathway
10.1007/s11030-025-11460-8 · 2026 · External reference
A novel designed fully peptide-based PROTAC, FPP29, demonstrates its potent cytotoxic effects to liver cancer HCCLM3 cells by targeting FOXM1
10.1016/j.bioorg.2025.108626 · 2025 · External reference
Development of an AlphaScreen assay for discovery of inhibitors of low-affinity glycan-lectin interactions
10.1016/j.ab.2013.04.028 · 2013 · External reference
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth
10.1186/s13045-022-01258-8 · 2022 · External reference
Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide
10.1016/j.bmc.2019.115228 · 2020 · External reference
Design, synthesis, and evaluation of BCL-2 targeting PROTACs
2024 · External reference
Target identification using drug affinity responsive target stability (DARTS)
10.1002/9780470559277.ch110180 · 2011 · External reference
Novel proteolysis-targeting chimera targeting RAD51 for the treatment of triple-negative breast cancer
2025 · External reference
Elaboration and profiling of the first OSBP degrader issued from natural Schweinfurthins
10.1016/j.bioorg.2025.108909 · 2025 · External reference
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability
10.1038/nprot.2007.321 · 2007 · External reference
Crystal structures of DCAF1-PROTAC-WDR5 ternary complexes provide insight into DCAF1 substrate specificity
10.1038/s41467-024-54500-x · 2024 · External reference
An in vitro pull-down assay of the E3 ligase:PROTAC:substrate ternary complex to identify effective PROTACs
10.1007/978-1-0716-1665-9_7 · 2021 · External reference
Mechanistic and structural features of PROTAC ternary complexes
10.1007/978-1-0716-1665-9_5 · 2021 · External reference
Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation
10.1038/s41467-023-39904-5 · 2023 · External reference
Degradation of protein kinases: ternary complex, cooperativity, and selectivity
10.1021/acsmedchemlett.1c00543 · 2021 · External reference
Monitoring PROTAC interactions in biochemical assays using Lumit immunoassays
10.1016/bs.mie.2022.08.055 · 2023 · External reference
Comparative analysis of biophysical methods for monitoring protein proximity induction in the development of small molecule degraders
10.1016/j.bbagen.2023.130398 · 2023 · External reference
A comparison of ALPHAScreen, TR-FRET, and TRF as assay methods for FXR nuclear receptors
10.1177/108705710200700102 · 2002 · External reference
General stepwise approach to optimize a TR-FRET assay for characterizing the BRD/PROTAC/CRBN ternary complex
10.1021/acsptsci.1c00032 · 2021 · External reference
SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate
10.1021/acschembio.9b00092 · 2019 · External reference
HTRF: a technology tailored for drug discovery – a review of theoretical aspects and recent applications
10.2174/1875397300903010022 · 2009 · External reference
Comparing flow cytometry QBeads PlexScreen assays with other immunoassays for determining multiple analytes
10.1177/2472555218771610 · 2018 · External reference
Development of two novel high-throughput assays to quantify ubiquitylated proteins in cell lysates: application to screening of new anti-malarials
10.1186/s12936-015-0708-1 · 2015 · External reference
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy
10.1084/jem.20231519 · 2024 · External reference
Protocol to test for the formation of ternary protein complexes in vivo or in vitro using a two-step immunoprecipitation approach
10.1016/j.xpro.2024.103080 · 2024 · External reference
Synthesis and evaluation of AS1411-lenalidomide-targeted degradation chimera in antitumor therapy
10.3390/ph18121867 · 2025 · External reference
Proximity ligation assay for detecting protein-protein interactions and protein modifications in cells and tissues in situ
10.1002/cpcb.115 · 2020 · External reference
Proximity ligation assay (PLA)
10.1002/cpim.58 · 2018 · External reference
Kinetic detection of E3:PROTAC:target ternary complexes using NanoBRET technology in live cells
10.1007/978-1-0716-1665-9_8 · 2021 · External reference
NanoBRET—a novel BRET platform for the analysis of protein-protein interactions
10.1021/acschembio.5b00143 · 2015 · External reference
Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization
10.1016/j.chembiol.2023.06.002 · 2023 · External reference
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
10.1038/s41591-019-0668-z · 2019 · External reference
Discovery of PZ671, a highly potent and in vivo active CRBN-recruiting Bcl-xL degrader
10.1039/d5md00119f · 2025 · External reference
Structural basis of PROTAC cooperative recognition for selective protein degradation
10.1038/nchembio.2329 · 2017 · External reference
Post-translational regulation of ubiquitin signaling
10.1083/jcb.201902074 · 2019 · External reference
Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities
10.1038/embor.2009.192 · 2009 · External reference
Accelerating PROTAC drug discovery: establishing a relationship between ubiquitination and target protein degradation
10.1016/j.bbrc.2022.08.048 · 2022 · External reference
BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes
10.1080/15384047.2022.2125748 · 2022 · External reference
DNA-templated spatially controlled proteolysis targeting chimera for cyclin D1-CDK4/6 complex protein degradation
10.1021/jacs.5c04918 · 2025 · External reference
Discovery of KRas G12C-IN-3 and pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity
10.1016/j.bioorg.2021.105447 · 2021 · External reference
Structure-based discovery of selective histone deacetylase 8 degraders with potent anticancer activity
10.1021/acs.jmedchem.2c00739 · 2023 · External reference
Design, synthesis, and evaluation of VHL-based EZH2 degraders to enhance therapeutic activity against lymphoma
10.1021/acs.jmedchem.1c00460 · 2021 · External reference
Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor
10.1016/j.ejmech.2021.113922 · 2022 · External reference
MicroRNA-triggered programmable DNA-encoded pre-PROTACs for cell-selective and controlled protein degradation
10.1002/anie.202415323 · 2025 · External reference
Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy
10.1038/s41401-024-01266-z · 2024 · External reference
Proteolysis targeting chimeras (PROTACs) based on imatinib induced degradation of BCR-ABL in K562 cells
2023 · External reference
Design, synthesis, and evaluation of VHL-based EZH2 degraders for breast cancer
10.1016/j.bioorg.2023.107078 · 2024 · External reference
A PROTAC peptide induces durable β-catenin degradation and suppresses Wnt-dependent intestinal cancer
10.1038/s41421-020-0171-1 · 2020 · External reference
Proteolysis targeting chimeras (PROTACs) based on promiscuous kinase inhibitor synergistically induce cancer cell apoptosis through multiple mechanisms
10.1002/slct.202203463 · 2022 · External reference
Novel amphiphilic PROTAC with enhanced pharmacokinetic properties for ALK protein degradation
10.1021/acs.jmedchem.3c02340 · 2024 · External reference
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity
10.1016/j.ejmech.2020.112186 · 2020 · External reference
Discovery of Novel PROTAC SIRT6 degraders with potent efficacy against hepatocellular carcinoma
10.1021/acs.jmedchem.4c01223 · 2024 · External reference
Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC
10.1016/j.ejmech.2021.114088 · 2022 · External reference
Targeted degradation of CD147 proteins in melanoma
10.1016/j.bioorg.2020.104453 · 2020 · External reference
Discovery of the first-in-class G9a/GLP PROTAC degrader
10.1021/acs.jmedchem.3c02394 · 2024 · External reference
Sunitinib-based proteolysis targeting chimeras (PROTACs) reduced the protein levels of FLT-3 and c-KIT in leukemia cell lines
10.1016/j.bmcl.2022.129041 · 2022 · External reference
High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma
10.1016/j.bcp.2019.03.023 · 2019 · External reference
GLUTs-facilitated targeting BRD4 degradation in breast cancer through carbohydrate-conjugated PROTACs
10.1021/acs.jmedchem.5c00468 · 2025 · External reference
Discovery of dual BCL-xL/BCL-w degraders by exploiting the bis(sulfonyl)benzene ring of ABT-263 as a linkage vector
10.1021/acs.jmedchem.5c01834 · 2025 · External reference
Pt(IV)-PROTAC complexes with synergistic antitumor activity and enhanced membrane permeability
10.1021/acs.jmedchem.4c02909 · 2025 · External reference
Development of highly potent and selective oncogenic KRASG12D PROTAC degraders
2025 · External reference
Selective degradation of TEADs by a PROTAC molecule exhibited robust anticancer efficacy in vitro and in vivo
10.1021/acs.jmedchem.4c02884 · 2025 · External reference
Discovery of the novel celastrol-based PROTACs for the treatment of non-small cell lung cancer
10.1007/s11030-025-11140-7 · 2025 · External reference
A selective RPL15 PROTAC degrader enhances anti-PD-1 immunotherapy in a murine melanoma tumor model
10.1038/s41388-025-03641-4 · 2025 · External reference
Discovery and optimization of potent PROTAC degraders of phosphoinositide 3-kinase with significant in vivo anticancer efficacy
10.1021/acs.jmedchem.5c00679 · 2025 · External reference
Utilizing the HiBiT system to identify CARM1 degraders for targeted cancer therapy
2026 · External reference
Targeted degradation of endogenous YAP by nanobody bioPROTAC inhibits tumor progression
10.1038/s41467-025-64426-7 · 2025 · External reference
ARV-771 acts as an inducer of cell cycle arrest and apoptosis to suppress hepatocellular carcinoma progression
2022 · External reference
Pomalidomide hybrids act as proteolysis targeting chimeras: synthesis, anticancer activity and B-Raf degradation
10.1016/j.bioorg.2019.03.035 · 2019 · External reference
A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death
10.1016/j.immuni.2024.04.025 · 2024 · External reference
Identification of a novel azaspirooxindolinone-based PROTAC for selective BTK degradation and enhanced anticancer activity
10.1016/j.bioorg.2025.108316 · 2025 · External reference
Linker-free PROTACs efficiently induce the degradation of oncoproteins
10.1038/s41467-025-60107-7 · 2025 · External reference
The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells
10.1158/1535-7163.mct-11-0401 · 2011 · External reference
TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia
10.1038/s41388-020-01586-4 · 2021 · External reference
Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs
10.1039/d0cc03243c · 2020 · External reference
Targeted protein degradation: design considerations for PROTAC development
10.1002/cpz1.611 · 2022 · External reference
ARV-825 demonstrates antitumor activity in gastric cancer via MYC-targets and G2M-checkpoint signaling pathways
10.3389/fonc.2021.753119 · 2021 · External reference
Discovery of highly potent dual GSPT1/BRD4 degraders with anti-AML activity
10.1016/j.ejmech.2025.117381 · 2025 · External reference
Unresolved reference
External reference
The necessity of and strategies for improving confidence in the accuracy of western blots
10.1586/14789450.2014.939635 · 2014 · External reference
Technical considerations for contemporary western blot techniques
10.1007/978-1-0716-1186-9_29 · 2021 · External reference
Human adipose tissue protein analyses using capillary western blot technology
10.1038/s41387-018-0030-4 · 2018 · External reference
Protocols for monitoring unconventional protein secretion using luminescence and trapping approaches
10.1002/cpz1.70326 · 2026 · External reference
Quantitative live-cell kinetic degradation and mechanistic profiling of PROTAC mode of action
10.1021/acschembio.8b00692 · 2018 · External reference
Ubiquilins chaperone and triage mitochondrial membrane proteins for degradation
10.1016/j.molcel.2016.05.020 · 2016 · External reference
Dual fluorescence cytometry assay to assess cellular protein levels
10.21769/bioprotoc.3597 · 2020 · External reference
Effects of biguanide-PROTACs in pancreatic cancer cells
10.3390/molecules29225329 · 2024 · External reference
Design, synthesis, and biological evaluation of proteolysis targeting chimeras (PROTACs) for the dual degradation of IGF-1R and Src
10.3390/molecules25081948 · 2020 · External reference
Discovery of a PROTAC targeting ALK with in vivo activity
10.1016/j.ejmech.2020.113150 · 2021 · External reference
Design, synthesis, and biological evaluation of novel protopanoxadiol derivatives based PROTACs technology for the treatment of lung cancer
10.1016/j.bioorg.2022.106327 · 2023 · External reference
Susceptibility of lung carcinoma cells to nanostructured lipid carrier of ARV-825, a BRD4 degrading proteolysis targeting chimera
10.1007/s11095-022-03184-3 · 2022 · External reference
Design and linkage optimization of ursane-thalidomide-based PROTACs and identification of their targeted-degradation properties to MDM2 protein
10.1016/j.bioorg.2021.104901 · 2021 · External reference
Discovery of the first examples of threonine tyrosine kinase PROTAC degraders
10.1021/acs.jmedchem.1c01768 · 2022 · External reference
Nanoformulation of PROteolysis TArgeting Chimera targeting ‘undruggable’ c-Myc for the treatment of pancreatic cancer
10.2217/nnm-2020-0156 · 2020 · External reference
Design, synthesis and biological evaluation of novel TMPRSS2-PROTACs with florosubstituted 4-guanidino-N-phenylbenzamide derivative ligands
10.1016/j.bmc.2024.117982 · 2024 · External reference
Targeting CDK9 in cancer: an integrated approach of combining in silico screening with experimental validation for novel degraders
10.3390/cimb46030111 · 2024 · External reference
BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade
10.1038/s41388-021-02041-8 · 2021 · External reference
New thalidomide-resembling dicarboximides target ABC50 protein and show antileukemic and immunomodulatory activities
10.3390/biom9090446 · 2019 · External reference
Hydroxamic acids immobilized on resins (HAIRs): synthesis of dual-targeting HDAC inhibitors and HDAC degraders (PROTACs)
10.1002/anie.202006725 · 2020 · External reference
Checkpoint nano-PROTACs for activatable cancer photo-immunotherapy
2023 · External reference
Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia
10.1016/j.bioorg.2024.107319 · 2024 · External reference
Targeting BET proteins with a PROTAC molecule elicits potent anticancer activity in HCC cells
10.3389/fonc.2019.01471 · 2019 · External reference
Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer
2022 · External reference
Controlled bioorthogonal activation of Bromodomain-containing protein 4 degrader by co-delivery of PROTAC and Pd-catalyst for tumor-specific therapy
10.1016/j.jconrel.2024.08.032 · 2024 · External reference
Rational design and synthesis of HSF1-PROTACs for anticancer drug development
10.3390/molecules27051655 · 2022 · External reference
Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression
10.1186/s13046-022-02483-2 · 2022 · External reference
Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFRWT and EGFRT790M
10.1080/14756366.2022.2062338 · 2022 · External reference
Replacing a cereblon ligand by a DDB1 and CUL4 associated factor 11 (DCAF11) recruiter converts a selective histone deacetylase 6 PROTAC into a pan-degrader
10.1002/cmdc.202500035 · 2025 · External reference
CDT prodrug therapy with cascade-activated PROTAC delivery platform for mutually reinforced ferroptosis and apoptosis-based therapy
2025 · External reference
A platinated prodrug leveraging PROTAC technology for targeted protein degradation and enhanced antitumor efficacy
10.1039/d5qi00605h · 2025 · External reference
Design, synthesis, and biological evaluation of RIPK1-targeting PROTACs
10.1007/s11030-025-11166-x · 2026 · External reference
Design, synthesis, and anticancer activity evaluation of the new SHP2 degraders
10.1002/slct.202405728 · 2025 · External reference
Design and synthesis of novel HDAC6 inhibitor dimer as HDAC6 degrader for cancer treatment by palladium catalysed dimerisation
10.1080/14756366.2025.2468355 · 2025 · External reference
Targeting of Brahma-related gene-1 (BRG1) overcomes paclitaxel-induced multidrug resistance caused by overexpression of the subset of ATP-binding cassette (ABC) transporters
10.1016/j.jpet.2025.103772 · 2025 · External reference
PROTACs: emerging targeted protein degradation approaches for advanced druggable strategies
10.3390/molecules28104014 · 2023 · External reference
Methods to accelerate PROTAC drug discovery
10.1042/bcj20243018 · 2025 · External reference
Unlocking the potential of camel milk-derived exosomes as novel delivery systems: enhanced bioavailability of ARV-825 PROTAC for cancer therapy
10.3390/pharmaceutics16081070 · 2024 · External reference
An overview of the current state of cell viability assessment methods using OECD classification
10.3390/ijms26010220 · 2024 · External reference
In vitro cell death determination for drug discovery: a landscape review of real issues
10.1177/1179670717691251 · 2017 · External reference
Comparison of cytotoxicity evaluation of anticancer drugs between real-time cell analysis and CCK-8 method
10.1021/acsomega.9b01142 · 2019 · External reference
PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis
10.1038/s41419-019-2022-2 · 2019 · External reference
Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition
10.1186/s12885-025-14361-z · 2025 · External reference
A novel β-carboline alkaloid derivative targeting MDM2-p53 pathway suppresses colorectal cancer progression
10.1007/s13402-025-01111-3 · 2025 · External reference
Preclinical mouse cancer models: a maze of opportunities and challenges
10.1016/j.cell.2015.08.068 · 2015 · External reference
Target validation using PROTACs: applying the four pillars framework
10.1177/2472555220979584 · 2021 · External reference
When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry—the red, brown, and blue technique
10.1177/0300985813505879 · 2014 · External reference
Intraperitoneal route of drug administration: should it be used in experimental animal studies?
10.1007/s11095-019-2745-x · 2019 · External reference
Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation
10.1039/d1cs00762a · 2022 · External reference
Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs
10.1038/s43856-024-00505-y · 2024 · External reference
PK/PD modeling of targeted protein degraders: charting new waters and navigating the shallows
10.1016/j.drudis.2025.104311 · 2025 · External reference
Development and validation of LC-MS/MS methods for the pharmacokinetic assessment of the PROTACs bavdeglutamide (ARV-110) and vepdegestrant (ARV-471)
10.1016/j.jpba.2024.116348 · 2024 · External reference
Proximity-based modalities for biology and medicine
10.1021/acscentsci.3c00395 · 2023 · External reference
Direct-to-biology accelerates PROTAC synthesis and the evaluation of linker effects on permeability and degradation
10.1021/acsmedchemlett.2c00124 · 2022 · External reference
